Associated Papers
Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment.
Batar P et al.
Current Oncology (toronto, Ont.), 2025
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ et al.
Leukemia, 2024
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.
Liu H et al.
European Journal of Medicinal Chemistry, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D et al.
Critical Reviews in Oncology/hematology, 2022
Select a paper to view details